IOVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Iovance Biotherapeutics Inc (IOVA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, improving financial performance, and favorable analyst sentiment, making it an attractive opportunity despite some profitability challenges.
The stock is in a bullish trend with MACD positively expanding and above zero, RSI at 91.164 indicating overbought conditions, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). Key resistance is at $4.84, and the stock is trading near its resistance level. While overbought conditions suggest caution, the overall trend remains positive.
["Revenue increased by 60.6% YoY in 2025, driven by strong demand for Amtagvi.", "Amtagvi received Fast Track Designation from the FDA for treating non-small cell lung cancer, expediting its development process.", "Iovance is expanding its market reach by seeking approvals in the EU, UK, and Australia.", "Hedge funds have significantly increased their buying activity by 296.59% over the last quarter.", "Analyst upgrades and increased price targets, with Barclays raising the target to $11 and Citizens upgrading to Outperform."]
["The company faces profitability challenges due to the complex manufacturing and administration processes for Amtagvi.", "Net income dropped by -8.47% YoY in Q4 2025, and EPS declined by -30.77% YoY."]
In Q4 2025, revenue increased by 17.74% YoY to $86.77 million, gross margin improved to 39.35% (up 3.01% YoY), but net income dropped to -$71.9 million (-8.47% YoY), and EPS fell to -0.18 (-30.77% YoY). Despite the net income decline, revenue growth and margin improvements indicate operational progress.
Analysts are increasingly positive on Iovance. Barclays raised its price target to $11 with an Overweight rating, Citizens upgraded the stock to Outperform with a $5 target, and Chardan maintained a Buy rating with a $16 target. Analysts highlight strong revenue growth, operational improvements, and a promising pipeline, viewing the stock as undervalued at current levels.
